DLD Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

DLD Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-396,600	Closed	-$17.9M	–	388
2025 Q3	$17.9M	Buy	+396,600	New	+$18.5M	1.29%	20
2019 Q2	–	Sell	-300,000	Closed	-$14.3M	–	94
2019 Q1	$14.3M	Buy	+300,000	New	+$14.9M	0.53%	32
2017 Q4	–	Sell	-400,000	Closed	-$25.5M	–	83
2017 Q3	$25.5M	Buy	+400,000	New	+$23.4M	2.51%	13

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DLD Asset Management's BMY Position: Q4 2025 in Review

DLD Asset Management sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 12,827 shares — an estimated $578K sold.

DLD Asset Management first reported a position in BMY in Q3 2025 and held it in 1 quarter. The position peaked at $578K in Q3 2025. 2,456 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

DLD Asset Management reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
DLD Asset Management sold 12,827 Bristol-Myers Squibb shares in Q4 2025, an estimated $578K.
DLD Asset Management first reported a position in Bristol-Myers Squibb in Q3 2025 and held it in 1 quarter.
DLD Asset Management's Bristol-Myers Squibb position peaked at $578K in Q3 2025.
2,456 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on DLD Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.